Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc is trading at $11.93, up 2.40% on the session. The 50 day average sits at $12.44 and the 200 day at $8.05, which puts the stock in a uptrend. RSI is at 50.1, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $11.20 with resistance near $12.53, so that band frames the current range. Average daily movement is roughly $0.78, or about 6.6% of the share price, which is what any stop placement has to allow for. The overall health score of 57 out of 100 combines a trend score of 53, momentum of 69 and a risk score of 46.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.